Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status

Author:

Sikora Dominika1ORCID,Kiś Jacek2,Stępień Ewa1,Drop Bartłomiej3,Polz-Dacewicz Małgorzata1ORCID

Affiliation:

1. Department of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, 20-093 Lublin, Poland

2. 1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, Poland

3. Department of Medical Informatics and Statistics with e-Health Lab, Medical University of Lublin, 20-090 Lublin, Poland

Abstract

The relationship between Toll-like receptors (TLRs) and prostate cancer (PCa) is complex due to the presence of the Epstein–Barr virus (EBV) infection, which has been identified as a predisposing factor for some cancers, including PCa. The present study aims to investigate these complex links by examining the levels of selected TLRs and the potential impact of EBV infection on PCa. Therefore, we examined the serum of patients with PCa. The study compared EBV(+) patients to risk groups, the Gleason score (GS), and the T-trait. Additionally, the correlation between TLR and antibody levels was examined. The results indicated that higher levels of TLR-2 and TLR-9 were observed in more advanced PCa. The findings of this study may contribute to a deeper understanding of the role of viral infections in PCa and provide information on future strategies for the diagnosis, prevention, and treatment of these malignancies.

Funder

Medical University of Lublin

Publisher

MDPI AG

Reference50 articles.

1. World Health Organization (2024, April 20). The Global Cancer Observatory—All Rights Reserved. December 2020. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf.

2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2024

3. (2024, April 20). Prostate Cancer—Is It Worth Getting Tested?, Available online: https://pacjent.gov.pl.

4. Epidemiology of Prostate Cancer;Rawla;World J. Oncol.,2019

5. Rak prostaty—Aktualne możliwości terapeutyczne;Wardecki;Farm. Pol.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3